Pediatrix Medical Group (NYSE:MD) Issues Quarterly Earnings Results

Pediatrix Medical Group (NYSE:MD) announced its quarterly earnings data on Tuesday. The company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.04, FiscalAI reports. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The business had revenue of $487.78 million during the quarter, compared to analyst estimates of $478.49 million. During the same period last year, the firm posted $0.53 EPS. The company’s revenue was up 4.1% on a year-over-year basis.

Here are the key takeaways from Pediatrix Medical Group’s conference call:

• Q2 adjusted EBITDA was $76 million, and management reaffirmed its 2026 adjusted EBITDA outlook of $280 million–$300 million.
• Consolidated revenue increased 4%, with same-unit revenue up 2% as stronger RCM collections, favorable payer mix, and higher patient acuity more than offset lower volumes.
• Same-unit patient service volumes declined 2%, including a 3% decrease in NICU days; management expects full-year volume to be flat to slightly down and said RCM collection benefits will begin to fade in the second half.
• The company repurchased nearly 2 million shares during the quarter, bringing total buybacks since August 2025 to 7 million shares and reducing shares outstanding to 81 million.
• Pediatrix is pursuing growth through tele-hybrid services, obstetric hospitalist programs, acquisitions, and potential joint ventures in women’s and children’s healthcare, while emphasizing disciplined financial and operating returns.

Pediatrix Medical Group Trading Up 6.3%

NYSE:MD traded up $1.55 during midday trading on Wednesday, hitting $26.26. 344,590 shares of the company traded hands, compared to its average volume of 797,838. The firm has a market capitalization of $2.16 billion, a P/E ratio of 12.75 and a beta of 0.66. The firm’s fifty day moving average is $24.76 and its 200-day moving average is $22.54. Pediatrix Medical Group has a 12-month low of $12.95 and a 12-month high of $27.94. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.45.

Trending Headlines about Pediatrix Medical Group

Here are the key news stories impacting Pediatrix Medical Group this week:

• Positive Sentiment: Quarterly results exceeded expectations. Pediatrix reported adjusted earnings of $0.63 per share, above the $0.59 consensus estimate, while revenue of $487.8 million surpassed expectations of $478.5 million. Earnings also improved from $0.53 per share a year earlier. Pediatrix Medical Group Reports Second Quarter Results
• Positive Sentiment: Revenue and profitability remained solid. Revenue increased 4.1% year over year, and the company reported a 19.94% return on equity and a 9.02% net margin. Zacks also characterized the quarter as an earnings and revenue beat. Pediatrix Medical Group Beats Q2 Earnings and Revenue Estimates
• Neutral Sentiment: Management emphasized pricing rather than volume growth. The earnings call’s key theme was that higher pricing is offsetting weaker or limited patient-volume growth. That mix may support near-term revenue, but investors will likely monitor whether Pediatrix can generate sustainable volume gains. Pediatrix Medical Group Earnings Call: Pricing Over Volumes
• Negative Sentiment: The stock’s reaction indicates that investors focused on forward operating concerns. Although Pediatrix beat quarterly estimates, coverage highlighted a sharp decline in the shares after the report, suggesting that pricing-led growth, volume pressure, or cautious commentary outweighed the stronger-than-expected second-quarter numbers. Pediatrix Medical Group’s Q2 CY2026: Beats On Revenue But Stock Drops

Wall Street Analyst Weigh In

MD has been the topic of several research analyst reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Wednesday, June 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Pediatrix Medical Group in a report on Wednesday. Jefferies Financial Group reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Pediatrix Medical Group in a research note on Monday, April 20th. UBS Group increased their target price on Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Finally, Mizuho set a $24.00 price target on shares of Pediatrix Medical Group in a research report on Friday, May 8th. One analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $23.33.

Insider Buying and Selling at Pediatrix Medical Group

In other news, Director Shirley A. Weis sold 36,028 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total value of $855,665.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Ameriprise Financial Inc. boosted its holdings in Pediatrix Medical Group by 175.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock valued at $10,683,000 after acquiring an additional 474,186 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of Pediatrix Medical Group by 669.4% in the second quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company’s stock worth $6,832,000 after purchasing an additional 414,216 shares during the last quarter. Qube Research & Technologies Ltd increased its stake in Pediatrix Medical Group by 55.4% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,143,306 shares of the company’s stock worth $19,150,000 after buying an additional 407,780 shares during the period. Cubist Systematic Strategies LLC bought a new stake in Pediatrix Medical Group during the 2nd quarter valued at about $4,248,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in Pediatrix Medical Group during the 2nd quarter valued at about $4,214,000. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.